Computational and in vitro experimental analyses of the Anti-COVID-19 potential of Mortaparib and MortaparibPlus

Abstract

COVID-19 pandemic caused by SARS-CoV-2 virus has become a global health emergency. Although new vaccines have been generated and being implicated, discovery and application of novel preventive and control measures are warranted. We aimed to identify compound/s that may possess the potential to either block the entry of virus to host cells or attenuate its replication upon infection. Using host cell surface receptor expression (Angiotensin-converting enzyme 2 (ACE2) and Transmembrane protease serine 2 (TMPRSS2) analysis as an assay, we earlier screened several synthetic and natural compounds and identified candidates that showed ability to downregulate their expression. Here, we report experimental and computational analyses of two small molecules, Mortaparib and MortaparibPlus that were initially identified as dual novel inhibitors of mortalin and PARP-1, for their activity against SARS-CoV-2. In silico analyses showed that MortaparibPlus, but not Mortaparib, stably binds into the catalytic pocket of TMPRSS2. In vitro analysis of control and treated cells revealed that MortaparibPlus caused downregulation of ACE2 and TMPRSS2; Mortaparib did not show any effect. Furthermore, computational analysis on SARS-CoV-2 main protease (Mpro) that also predicted the inhibitory activity of MortaparibPlus. However, cell based anti-virus drug screening assay showed 30~60% viral inhibition in cells treated with non-toxic doses of either MortaparibPlus or Mortaparib. The data suggests that these two closely related compounds possess multimodal anti-COVID 19 activities. Whereas MortaparibPlus works through direct interactions/effects on the host cell surface receptors (ACE2 and TMPRSS2) and the virus protein (Mpro), Mortaparib involves independent mechanisms, elucidation of which warrants further studies.

Natural withanolides, an update

“…229 In addition, Kumar et al found that, similar to N3 inhibitor, withanone could interact with the highly conserved residues of the proteases of coronaviruses, suggesting that withanone might be developed for the treatment of COVID-19. 230 Through molecular dynamics simulation analysis, withanolide R and 2,3-dihydrowithaferin A were also reported to bind to the main protease and the spike proteins of SARS-CoV-2, respectively, with the lowest relative free energy. 231 All these compounds need in vitro and in vivo experiments to confirm their effects on SARS-CoV-2 and evaluate their potential therapeutic effects on COVID-19.…”

Herbo-mineral formulation, Divya-Swasari-Vati averts SARS-CoV-2 pseudovirus entry into human alveolar epithelial cells by interfering with spike protein-ACE 2 interaction and IL-6/TNF-α /NF-κB signaling

“…However, the efficacy of none of these treatment options was found to be optimal against COVID-19, let alone the severe side effects, especially for immunocompromised cancer and diabetic patients (Di Lorenzo et al, 2020). During the initial phase of the pandemic, several in silico studies reported potentially effective metabolites against SARS-CoV-2 infection (Balkrishna et al, 2021a;Balkrishna et al, 2021b;Kumar V. et al, 2021;. Several herbal plants target immune responses by reducing cytokine levels (Li S. et al, 2021).…”

ADMET profiling and molecular docking of potential antimicrobial peptides previously isolated from African catfish, Clarias gariepinus

“…The two antimicrobial peptides (ACAP-IV and ACAP-V) were docked against their respective target proteins. The molecular docking technique permits simultaneous investigation of thousands of molecules and later incorporates the ligand-target interactions to rank such molecules based on their binding affinities (Lionta et al, 2014;Kumar et al, 2020). The technique utilizes machine learning search algorithms to predict ligand-target binding sites and affinity (Shukla et al, 2020) and has been widely used to aid the discovery of several drugs including Captopril, Dorzolamide, Saquinavir, Zanamivir, Oseltamivir, Aliskiren, Boceprevir, Nolatrexed, TMI-005, LY-517717, Rupintrivir and NVP-AUY922 (Talele et al, 2010).…”